CytoMed Therapeutics Limited filed a 6-K announcing its Annual General Meeting on May 22, 2026, to adopt 2025 audited financial statements, re-elect directors, approve auditors, directors' fees, Code waiver, and share issuance authority.
Key takeaways
AGM scheduled for May 22, 2026 at 1 Commonwealth Lane, Singapore 149544.
Proposals include adoption of audited financial statements for FY ended December 31, 2025 (Singapore statutory and Form 20-F).
Re-election of directors Dr. YEW Chak Hua and Dr. TOH Keng Kiat, both eligible and offering for re-election.
Ratification of WWC, P.C. and KE Trust PAC as independent auditors for FY ending December 31, 2026.
Approval sought for US$70,000 directors' fees for FY 2026; Prof. LOH Yuin Han waived compensation.
Proposal to waive Singapore Code on Take-overs and Mergers application, with SIC waiver intent on May 25, 2026.
Authorization for directors to issue new ordinary shares until next AGM.